Jian Li

Monash University

Professor Jian Li (PhD 2002) is an elected Fellow of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, and the American Academy of Microbiology. Jian heads the Laboratory of Antimicrobial Systems Pharmacology at the Biomedicine Discovery Institute, Monash University in Melbourne, Australia. Dr Li has an internationally recognized track record in antimicrobial pharmacology and drug discovery. The majority of modern polymyxin pharmacology data were reported by Jian’s group, which led to the first scientifically-based dosing recommendations for colistin and have improved clinical practice worldwide. Jian’s group has developed a novel lipopeptide drug (BRII-693 [QPX9003]) against Gram-negative ‘superbugs’ from concept to clinical trials. Dr Li has 442 publications with 30,220 citations and an h-index of 84, and is the Editor-in-Chief of the first book on polymyxins (2019, >63,000 downloads). Jian is a Web of Science® Highly Cited Researcher in pharmacology & toxicology (2015 – 2017, 2022). Dr Li is President of the International Society of Antimicrobial Pharmacology (ISAP) and Chair of the Anti-infective Pharmacology Group of the International Society of Antimicrobial Chemotherapy (ISAC). Dr Li is Editor-in-Chief of the International Journal of Antimicrobial Agents and an invited reviewer for 194 international journals and 32 international funding bodies (e.g. NIH, Wellcome Trust). Professor Li has received numerous prestigious awards, including the NHMRC’s Ten of the Best Research Projects (2015), and the Jacques Miller Medal for Experimental Biomedicine by the Australian Academy of Science (2017).